Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Celltrion Inc sales and marketing update

    Celltrion Inc. (KOSDAQ:068270), Incheon, South Korea Business: Autoimmune, Biosimilars Celltrion launched Remsima infliximab, a biosimilar of Remicade from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & …

    Published on 3/2/2015
  • AbbVie Inc, Gilead, GKV-Spitzenverband sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GKV-Spitzenverband, Berlin, Germany Business: Infectious Germanys statutory health insurer GKV-Spitzenverband said Gilead …

    Published on 2/23/2015
  • Hisamitsu Pharmaceutical Co. Inc sales and marketing update

    Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530), Tosu, Japan Business: Musculoskeletal, Drug delivery Hisamitsus Noven Pharmaceuticals Inc. subsidiary launched 0.025 mg/day Minivelle estradiol transdermal system in the U…

    Published on 2/23/2015
  • Hospira Inc sales and marketing update

    Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Business: Autoimmune, Biosimilars Hospira launched Inflectra infliximab in major European markets, including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, the …

    Published on 2/23/2015
  • MannKind Corp, Sanofi sales and marketing update

    MannKind Corp. (NASDAQ:MNKD), Valencia, Calif. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic, Drug delivery Sanofi launched Afrezza in the U.S. to treat adults with Type I and II diabetes.…

    Published on 2/23/2015
  • Octapharma sales and marketing update

    Octapharma AG, Lachen, Switzerland Business: Hematology Octapharmas Octapharma USA subsidiary launched a co-pay assistance program for commercially insured patients taking wilate for von Willebrands Disease (VWD). The …

    Published on 2/23/2015
  • AstraZeneca, Clinigen Group sales and marketing update

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Clinigen Group plc (LSE:CLIN), Burton-on-Trent, U.K. Business: Infectious Clinigen launched an international global access program for AstraZenecas CAZ-AVI. CAZ-AVI is a…

    Published on 2/16/2015
  • Cynvenio Biosystems sales and marketing update

    Cynvenio Biosystems Inc., Westlake Village, Calif. Business: Diagnostic Cynvenio is launching its LiquidBiopsy platform in the U.S. this month. LiquidBiopsy uses a blood sample to perform sequence analysis and genomic …

    Published on 2/16/2015
  • Daiichi Sankyo sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cardiovascular Daiichi launched once-daily oral Savaysa edoxaban in the U.S. to reduce the risk of stroke and systemic embolism in patients with non-valvular…

    Published on 2/16/2015
  • Eli Lilly sales and marketing update

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Cancer The pharmas Lilly Oncology unit launched the PACE Continuous Innovation Indicators (CII) tool to measure progress against cancer. CII will initially …

    Published on 2/16/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Neurology Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor antagonist is available in 5, 10, 15 and …

    Published on 2/16/2015
  • Multiplicom sales and marketing update

    Multiplicom N.V., Niel, Belgium Business: Diagnostic Multiplicom began enrolling molecular diagnostic laboratories as part of an early access program for Clarigo Dx, a non-invasive prenatal diagnostic that detects fetal…

    Published on 2/16/2015
  • Premaitha Health sales and marketing update

    Premaitha Health plc (LSE:NIPT), Manchester, U.K. Business: Diagnostic Premaitha received CE Mark approval and launched its Iona non-invasive prenatal in vitro diagnostic in Europe to assess the risk of a fetus having …

    Published on 2/16/2015
  • UnitedHealth Group, University of Texas MD Anderson Cancer Center sales and marketing update

    UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer The center and UnitedHealthcare launched a bundle payment model for head and neck …

    Published on 2/16/2015
  • Exact Sciences, CMS sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Centers for Medicare & Medicaid Services, Baltimore, Md. Business: Diagnostic Exact Sciences said CMS updated its 2015 reimbursement rate for Exacts Cologuard colon …

    Published on 2/9/2015
  • Galderma sales and marketing update

    Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Restylane Silk Injectable Gel with lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of …

    Published on 2/9/2015
  • GenomeDx Biosciences sales and marketing update

    GenomeDx Biosciences Inc., Vancouver, B.C. Business: Diagnostic GenomeDx said Medicare administrative contractor Palmetto GBA issued a positive coverage policy through its MolDX Program for GenomeDxs Decipher Prostate …

    Published on 2/9/2015
  • Gilead, Catamaran, Cigna Corp. sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Catamaran Corp. (NASDAQ:CTRX; TSX:CCT), Schaumburg, Ill. Cigna Corp. (NYSE:CI), Bloomfield, Conn. Business: Infectious Catamaran selected Gileads Harvoni …

    Published on 2/9/2015
  • AbbVie sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Infectious Missouris Medicaid agency said it will make AbbVies Viekira Pak its preferred regimen to treat HCV infection in exchange for undisclosed rebates. Missouri is …

    Published on 2/2/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary Boehringer launched Spiriva Respimat tiotropium bromide inhalation spray in the U.S. to treat bronchospasm associated with chronic obstructive pulmonary …

    Published on 2/2/2015
  • Gilead, Envision Pharmaceutical Holdings LLC, UnitedHealth Group sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Envision Pharmaceutical Holdings LLC, Twinsburg, Ohio UnitedHealth Group Inc. (NYSE:UNH), Minneapolis, Minn. Business: Infectious UnitedHealth selected Gileads …

    Published on 2/2/2015
  • GlaxoSmithKline sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Inflammation, Pulmonary GlaxoSmithKline launched two drugs in the U.S.: Arnuity Ellipta fluticasone furoate inhalation powder to treat asthma; and Incruse …

    Published on 2/2/2015
  • Lupin sales and marketing update

    Lupin Ltd. (NSE:LUPIN; BSE:500257), Mumbai, India Business: Neurology Lupins Lupin Pharmaceuticals Inc. subsidiary launched an authorized generic of pain drug Celebrex celecoxib in the U.S. in 50, 100, 200 and 400 mg …

    Published on 2/2/2015
  • Purdue Pharma sales and marketing update

    Purdue Pharma L.P., Stamford, Conn. Business: Neurology Purdue launched Hysingla ER in the U.S. to manage long-term severe pain. Hysingla is a once-daily, extended-release (ER) formulation of hydrocodone bitartrate …

    Published on 2/2/2015
  • Takeda Pharmaceuticals Co. Ltd. sales and marketing update

    Takeda Pharmaceuticals Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Other Takeda launched IV fomepizole in Japan to treat ethylene glycol and methanol poisoning. Takeda has exclusive, Japanese rights to develop and …

    Published on 2/2/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993